Does Semaglutide Cause Otic Neuritis?
No, semaglutide does not cause otic neuritis, but it can cause eustachian tube dysfunction (ETD) and patulous ETD (PETD) due to rapid weight loss and tissue volume reduction in the nasopharynx.
The Actual Otologic Adverse Events
The FDA drug label for semaglutide does not list otic neuritis or any ear-related adverse events as recognized complications 1. The documented adverse events focus on gastrointestinal effects, thyroid C-cell tumors, hypoglycemia, and cardiovascular changes—but not otic neuritis.
However, semaglutide does cause ear-related problems through a different mechanism: rapid weight loss leading to loss of peritubal fat pad tissue. A 2025 systematic review and FDA adverse event database analysis found 958 otologic adverse events (0.99% of all adverse events) among GLP-1 RA users, with the most common being hypoacusis (hearing loss), vertigo, deafness, and tinnitus 2. Critically, this study documented the first cases of patulous eustachian tube dysfunction (PETD) associated with GLP-1 RAs, confirmed by nasal endoscopy showing significant loss of tissue bulk in the anterior and posterior eustachian tube cushions 2.
The Mechanism: Weight Loss, Not Neuritis
The ear symptoms are not due to nerve inflammation (neuritis) but rather:
- Rapid fat loss in the nasopharyngeal tissues surrounding the eustachian tube
- Loss of the peritubal fat pad that normally helps maintain eustachian tube closure
- This creates autophony (hearing one's own voice loudly) and aural fullness
- The mechanism mirrors what occurs after bariatric surgery, which is well-established in the literature 2
Among GLP-1 RAs, dulaglutide had the highest absolute number of ETD-related adverse events (417), while exenatide had the highest proportion (1.52%), followed by semaglutide (1.17%) 2.
What About Optic Neuropathy?
Interestingly, semaglutide is associated with non-arteritic anterior ischemic optic neuropathy (NAION)—affecting the optic nerve, not the auditory nerve. A 2026 nationwide US Veterans study found a 2.33-fold increased risk of NAION in semaglutide initiators compared to SGLT2i initiators (HR 2.33; 95% CI 1.54-3.54), though the absolute risk remained low at 0.29% 3. This has been confirmed in case reports 4.
Clinical Implications
When patients on semaglutide report ear symptoms, think ETD/PETD, not neuritis:
- Symptoms to screen for: Autophony, aural fullness, hearing one's own breathing, muffled hearing
- Examination: Perform nasal endoscopy to assess peritubal fat pad volume
- Management: The condition is related to weight loss velocity and tissue volume changes
- Counseling: Inform patients this is a recognized but uncommon complication (approximately 1% of users)
The confusion between "otic neuritis" and actual otologic complications is important to clarify—the pathophysiology is mechanical (tissue loss) rather than inflammatory (nerve inflammation).